CNN

Esperion Announces Commercial Availability of the NEXLETOL™ (bempedoic acid) Tablet and Pledges a Conscientious Launch During Unprecedented Moment in Healthcare

– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine in the U.S. in Nearly 20 Years for Indicated Patients Awaiting a New Option – – Esperion Aims to Set New Industry Standard by ...
Healio

FDA approves expanded indications for bempedoic acid and combination tablet

Please provide your email address to receive an email when new articles are posted on . The FDA approved expanded indications for bempedoic acid and bempedoic acid plus ezetimibe for primary ...
Nasdaq

U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet

– Cardiovascular (CV) Risk Reduction Labels Remain on Track: in U.S. with PDUFA Date of March 31; in Europe with Anticipated Approval in 1H 2024 – ANN ARBOR, Mich., Dec. 13, 2023 (GLOBE NEWSWIRE) -- ...
Seeking Alpha

Esperion stock jumps as non-statin therapy shows clinical benefits across diverse patient groups

Esperion Therapeutics (NASDAQ:ESPR) shares gained 7% premarket on Monday after the company touted clinical benefits of NEXLETOL (bempedoic acid) tablets in diverse populations, including women, ...
Hosted on MSN

‘Acid reflux tablet saved my life’ – man’s hidden cancer discovered

A man said his hidden cancer was revealed – and life saved – by an acid reflux tablet. Grandad-of-seven Steven Wise, 71, had been suffering with painful acid reflux for a year. He was eventually ...
CNN

Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine

ANN ARBOR, Mich., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) announced today that the U.S. Food and Drug Administration (FDA) approved NEXLETOL™ (bempedoic acid) tablet, an oral, ...